ALMR
Alamar Biosciences, Inc.
$28.16
+7.07% 2026-10-20
Healthcare
ALMRSPY
1W
+19.7%
1M
-19.2%
3M
+12.0%
6M
+21.2%
YTD
–
1Y
–
Live chart
Loading live chart…
Grades vs sector
MomentumNot enough data yet–
Momentum
Not enough data yet
Percentile within its GICS sector across the S&P 1500.
GrowthNot enough data yet–
Growth
Not enough data yet
Percentile within its GICS sector across the S&P 1500.
ValueNot enough data yet–
Value
Not enough data yet
Percentile within its GICS sector across the S&P 1500.
ProfitabilityNot enough data yet–
Profitability
Not enough data yet
Percentile within its GICS sector across the S&P 1500.
RevisionsNot enough data yet–
Revisions
Not enough data yet
30-day change in analysts' current-year EPS estimate; graded across covered stocks.
Our models
Not held by any of our 5 live models right now.
Quality Growth
not ranked (outside this model's universe or screens)
Momentum Top 15not ranked (outside this model's universe or screens)
Momentum Blendnot in the current book
New Highs Growthnot ranked (outside this model's universe or screens)
Conviction 20not in the current book
News
More newsKardigan And 2 Founder Run Stocks To Own
Simply Wall St. · 21h ago
Cathie Wood Has Sold Nearly $18 Million of Meta in Days -- Here's What It Means
GuruFocus.com · Oct 13
Alamar Biosciences to Report Third Quarter 2026 Financial Results on November 3, 2026
GlobeNewswire · Oct 08
Alamar Biosciences Names Former Grail CEO Bob Ragusa to Board of Directors and Expands Leadership Team
GlobeNewswire · Oct 05
Lancet Neurology Study Using Alamar Biosciences’ Technology Reveals Divergent Biological Responses to Alzheimer’s Treatment
GlobeNewswire · Sep 24
Key stats
Market cap$2.0B
P/E (trailing)–
P/E (forward)-62.3
52-week range18.85 – 39.61
Revenue growth (YoY, latest qtr)+82.1%
Dividend yield0.00%
Analyst consensusBuy (5)
Mean price target$35.40 (+26%)
Valuation and fundamentals
Valuation & fundamentals
No US-GAAP 10-K/10-Q financials in SEC data (foreign filers report on Form 20-F, often under IFRS).
Earnings
Next report: 2026-11-03 · during market · EPS est -0.19
EstimateActual (beat)Actual (miss)
| Report | EPS est | Actual | Surprise |
|---|---|---|---|
| 2026-08-10 | -0.32 | -0.20 | +37.4% |
Quarterly revenue
| Quarter | Revenue | YoY |
|---|---|---|
| 2026-06-30 | $29.4M | – |
| 2026-03-31 | $26.0M | – |
| 2025-06-30 | $16.2M | – |
| 2025-03-31 | $13.1M | – |
Analyst actions
Stifel
PT $32
2026-08-11 · main
Buy → BuyPT $32
JP Morgan
PT $35
2026-08-11 · main
Overweight → OverweightPT $35
Leerink Partners
PT $35
2026-05-12 · init
→ OutperformPT $35
TD Cowen
PT $30
2026-05-12 · init
→ BuyPT $30
JP Morgan
PT $30
2026-05-12 · init
→ OverweightPT $30
Stifel
PT $28
2026-05-12 · init
→ BuyPT $28
Insider trades
Qiming Corporate Gp Vi, Ltd.
$54
10% owner · 2026-10-16
SELL$54
Qiming Corporate Gp Vi, Ltd.
$2.4K
10% owner · 2026-10-16
SELL$2.4K
Qiming Corporate Gp Vi, Ltd.
$567
10% owner · 2026-10-16
SELL$567
Qiming Corporate Gp Vi, Ltd.
$676
10% owner · 2026-10-16
SELL$676
Qiming Corporate Gp Vi, Ltd.
$83.9K
10% owner · 2026-10-15
SELL$83.9K
Qiming Corporate Gp Vi, Ltd.
$254
10% owner · 2026-10-15
SELL$254
Qiming Corporate Gp Vi, Ltd.
$3.1M
10% owner · 2026-10-15
SELL$3.1M
Qiming Corporate Gp Vi, Ltd.
$9.2K
10% owner · 2026-10-15
SELL$9.2K
Qiming Corporate Gp Vi, Ltd.
$727.2K
10% owner · 2026-10-15
SELL$727.2K
Qiming Corporate Gp Vi, Ltd.
$2.1K
10% owner · 2026-10-15
SELL$2.1K
Qiming Corporate Gp Vi, Ltd.
$870.6K
10% owner · 2026-10-15
SELL$870.6K
Qiming Corporate Gp Vi, Ltd.
$2.5K
10% owner · 2026-10-15
SELL$2.5K
Stats refreshed 2026-10-20 18:13:44 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now
coteau
Coteau Systematic Strategies publishes stock research and model portfolios. It doesn't manage money or give investment advice. Results are hypothetical unless marked Live. Data: Yahoo Finance (delayed) and SEC EDGAR.